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Abstract: Cyclin-dependent kinase 5 regulatory subunit 1 (CDK5R1) gene encodes for p35, the main
activator of Cyclin-dependent kinase 5 (CDK5). The active p35/CDK5 complex is involved in
numerous aspects of brain development and function, and its deregulation is closely associated to
Alzheimer’s disease (AD) onset and progression. We recently showed that miR-15/107 family can
negatively regulate CDK5R1 expression modifying mRNA stability. Interestingly, miRNAs belonging
to miR-15/107 family are downregulated in AD brain while CDK5R1 is upregulated. Long non-coding
RNAs (lncRNAs) are emerging as master regulators of gene expression, including miRNAs, and their
dysregulation has been implicated in the pathogenesis of AD. Here, we evaluated the existence of an
additional layer of CDK5R1 expression regulation provided by lncRNAs. In particular, we focused
on three lncRNAs potentially regulating CDK5R1 expression levels, based on existing data: NEAT1,
HOTAIR, and MALAT1. We demonstrated that NEAT1 and HOTAIR negatively regulate CDK5R1
mRNA levels, while MALAT1 has a positive effect. We also showed that all three lncRNAs positively
control miR-15/107 family of miRNAs. Moreover, we evaluated the expression of NEAT1, HOTAIR,
and MALAT1 in AD and control brain tissues. Interestingly, NEAT1 displayed increased expression
levels in temporal cortex and hippocampus of AD patients. Interestingly, we observed a strong
positive correlation between CDK5R1 and NEAT1 expression levels in brain tissues, suggesting a
possible neuroprotective role of NEAT1 in AD to compensate for increased CDK5R1 levels. Overall,
our work provides evidence of another level of CDK5R1 expression regulation mediated by lncRNAs
and points to NEAT1 as a biomarker, as well as a potential pharmacological target for AD therapy.
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1. Introduction
Alzheimer’s Disease (AD) is the most common neurodegenerative disorder, causing a severe and
permanent impairment of both cognitive and behavioral functions. It accounts for about 70% of the
50 million people suffering from dementia worldwide and it is currently estimated that, with global
population aging, the prevalence of AD will triple by 2050 [1], with a significant economic and social
burden on both patients’ families and society.
AD is characterized by a plethora of pathological features, including neuronal loss, dendritic
hypotrophy and synaptic alteration, microglial malfunction, cerebrovascular amyloid angiopathy,
inflammation, and mitochondrial dysfunction [2,3]. However, the most distinctive features are the
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presence of extracellular senile plaques, formed by fibrillary β-amyloid (Aβ) and neurofibrillary tangles
(NFTs), composed of hyperphosphorylated Tau [4]. Abnormal kinase activity is believed to play a
major role in AD pathogenesis [5]. In particular, deregulation of Cyclin-dependent kinase 5 (CDK5),
a proline-directed serine/threonine kinase involved in several developmental and physiological
processes in the central nervous system (CNS) [6,7], has been suggested to play a pivotal role in the
onset of the two main pathological hallmarks of AD by inducing Aβ peptide production and mediating
Tau protein hyperphosphorylation [8].
CDK5 requires the p35 regulatory subunit to become active and its kinase activity is strictly
dependent on the amount of its activator. p35 is encoded by the cyclin-dependent kinase 5 regulatory
subunit 1 (CDK5R1) gene, which displays a large and highly conserved 3′-UTR, suggestive of an
important role of post-transcriptional regulation in the control of its expression. Indeed, we previously
demonstrated that CDK5R1 expression is regulated at the post-transcriptional level by neuronal
ELAV (nELAV) RNA-binding proteins [9,10] and by heterogeneous nuclear ribonucleoproteins A2/B1
(hnRNP A2/B1) [10]. In addition, we recently found that the miR-15/107 family of microRNAs is also
involved in negatively regulating CDK5R1 expression. More interestingly, this group of microRNAs
turned out to be downregulated in the hippocampus and cerebral cortex of AD patients while CDK5R1
mRNA levels were upregulated in AD hippocampus [11].
An additional layer of complexity to the regulation of CDK5R1 expression that can be relevant
for AD pathogenesis might be provided by long non-coding RNAs (lncRNAs). LncRNAs are a highly
heterogeneous class of RNA molecules of more than 200 bases in length with no protein-coding capacity.
They are involved in the control of gene expression at multiple levels, from nuclear architecture to
transcription regulation, mRNA splicing and maturation to mRNA localization and stability, and
protein translation and stability to regulation of miRNA activity [12]. Owing to this versatility,
lncRNAs are now considered as master regulators of gene expression [13]. In particular, lncRNAs have
been shown to post-transcriptionally regulate the levels of several target genes by the formation of
lncRNA/miRNA/target gene axes, and the dysregulation of the crosstalk between the two types of
ncRNAs has been found to be a crucial contributor to disease pathogenesis [14].
The role of lncRNAs in malignancies and their significance as both diagnostic and prognostic
markers has been extensively studied and is well established [15], but an involvement of lncRNAs in the
pathogenesis of neurodegenerative diseases is now clearly emerging. In particular, different lncRNAs
have been found dysregulated in Alzheimer’s disease and involved in AD pathogenesis by promoting
β-amyloid production, including BACE1-AS, 17A, and NDM29 [16]. For example, the expression of
BACE1-AS, the antisense transcript of the β-secretase encoding gene BACE1, is upregulated in AD
brains specimens. BACE1-AS was reported to increase the stability of BACE1 mRNA and to prevent
the binding of miRNA 485-5p, therefore positively regulating BACE1 protein levels and promoting
Aβ42 synthesis [16,17].
In the present work, we focused on three different lncRNAs which had the potential for regulating
CDK5R1 expression levels and deserved to be analyzed in AD brain tissues, namely NEAT1, HOTAIR,
and MALAT1. NEAT1 (nuclear enriched abundant transcript 1) is a lncRNA that regulates gene
expression by binding to the promoter of active chromatin sites [18,19]. Moreover, NEAT1 is known to
act as a scaffold for paraspeckles [20], representing specific subnuclear bodies that are involved in gene
expression regulation by sequestration and retention of specific RNAs and proteins [21]. Relevantly,
NEAT1 levels were found to be deregulated in different neurodegenerative diseases [22]. MALAT1
(metastasis-associated lung adenocarcinoma transcript 1), also known as NEAT2 (nuclear-enriched
abundant transcript 2), is predominantly localized to nuclear speckles, where it regulates alternative
splicing by modulating the phosphorylation status of SR family of splicing factors [23]. MALAT1 has
been linked to several human tumors, in most cases being overexpressed in malignant tissues [24]. Both
NEAT1 and MALAT1 have been demonstrated to regulate the expression of members of the miR-15/107
group of miRNAs [25,26], which are known CDK5R1 negative regulators [11]. HOTAIR (HOX antisense
intergenic RNA) is transcribed from the antisense strand of the HOXC locus and represses expression
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of the downstream HOXD locus together with several genes on other chromosomes. HOTAIR is
involved in the control of cell apoptosis, growth, metastasis, angiogenesis, DNA repair and, like
MALAT1, it has been shown to be upregulated in different types of cancer [27]. Interestingly, HOTAIR
can also serve as a scaffold for Lysine-specific histone demethylase 1A (LSD1) complex and polycomb
repressive complex 2 (PRC2) [28]. Since the expression of CDK5R1 is repressed by LSD1 [29], HOTAIR
can potentially impact CDK5R1 levels.
Here, we demonstrated that NEAT1 and HOTAIR negatively regulate CDK5R1 mRNA levels,
while MALAT1 has a positive effect on CDK5R1 expression. We also showed that all three lncRNAs
positively control the levels of miR-15/107 family of microRNAs. Moreover, we evaluated the
expression of NEAT1, HOTAIR, and MALAT1 in AD and control brain tissues. Interestingly, NEAT1
displayed increased expression levels in temporal cortex and hippocampus of AD patients, compared
to controls. In addition, we observed a strong positive correlation between CDK5R1 and NEAT1
expression levels in brain tissues, suggesting a novel molecular marker of AD pathogenesis, warranting
further studies. Overall, our work provides evidence of another level of CDK5R1 expression regulation
mediated by long non-coding RNAs, which can also impact on Alzheimer’s disease research.
2. Results
2.1. NEAT1, HOTAIR, and MALAT1 Long Non-Coding RNAs Differently Regulate CDK5R1 Expression
In order to test the hypothesis that lncRNAs might be involved in the regulation of CDK5R1,
we analyzed the effect of NEAT1, HOTAIR, and MALAT1 downregulation on CDK5R1 expression.
We transfected HeLa cells with 10 nM of specific 2’OMe-PS antisense oligonucleotides (ASO) to
specifically knockdown the three lncRNAs. Total RNA was extracted 24 h after transfection and the
levels of lncRNAs and CDK5R1 mRNA were assessed by qRT-PCR. The analysis showed that NEAT1,
HOTAIR, and MALAT1 levels were reduced by 61%, 71%, and 78% respectively, compared to the
control oligonucleotide (Figure 1A). Remarkably, increased CDK5R1 transcript levels were observed
after NEAT1 and HOTAIR silencing, meaning that these two lncRNAs negatively regulate CDK5R1
expression (Figure 1B). On the contrary, CDK5R1 mRNA levels were significantly decreased after
MALAT1 silencing compared to controls, indicating a positive action of this lncRNA on CDK5R1
expression (Figure 1B).
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Figure 1. Effect of NEAT1, HOTAIR, and MAL T1 silencing on CDK5R1 mRNA levels. (A) NEAT1,
HOTAIR, and MALAT1 levels 24 h after transf with specific ASOs. Th lev ls of each lncRNA
were reduc d by at least 60%, compared to a control ASO (NC)-transfect d cells. (B) Increased CDK5R1
transcript levels were observed after NEAT1 and HOTAIR silencing, compared to the normal control.
On the contrary, CDK5R1 mRNA levels were significantly decreased after MALAT1 silencing. n = 5,
mean ± s.d., * p < 0.05, ** p < 0.01, Student’s t-test.
2.2. NEAT1, HOTAIR, and MALAT1 Upregulate miR-15/107 Expression
Since we previously demonstrated that CDK5R1 expression is negatively regulated by the
miR-15/107 group of microRNAs [11], we also verified by qRT-PCR on the RNA previously extracted
Int. J. Mol. Sci. 2018, 19, 2022 4 of 14
from HeLa cells if NEAT1, HOTAIR, and MALAT1 silencing was able to affect miR-15/107 expression.
The levels of all the analyzed miR-15/107 family members were reduced after NEAT1, HOTAIR, and
MALAT1 silencing, compared to the control treatment (Figure 2), being HOTAIR the most efficient
with a reduction of miRNA targets of about 50%. NEAT1 and MALAT1 led to a less pronounced but
significant reduction of all miRNAs, with the exception of miR-15b after NEAT1 knock-down, whose
reduction did not reach the statistical significance (Figure 2).
These data suggest that HOTAIR and NEAT1 might negatively regulate CDK5R1 expression
through a positive action on miR-15/107 levels. On the contrary, the positive effect of MALAT1 on
CDK5R1 mRNA cannot be explained by the action of these miRNAs, and a different mechanism must
be involved in MALAT1-mediated positive effect on CDK5R1 expression.
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Figure 2. Effect of NEAT1, HOTAIR, and MAL T1 silencing on iR-15/107 levels. Decreased levels of
all miR-15/107 miRNAs were det cted af r th knock-down of the thre lncR = 5, mean ± s.d.,
* p < 0.05, ** p < . 05, Student’s t-t st.
CDK5R1 also represents a target of EGR1 transcription factor whose expression is induced by
ERK/MAPK pathway ctivation [30]. Since MALAT1 has been described to be a posit ve modulator
of ERK/MAPK pathway [31], we evaluated the expression of EGR1 following MALAT1 silencing.
Consistently, qRT-PCR analysis showed that the levels of EGR1 are strongly reduced (83%) in cells
treated with MALAT1 specific antisense oligonucleotide, compared to normal control (Figure 3). These
results suggest that the positive regulation exerted by MALAT1 on CDK5R1 expression can be due to
MALAT1-mediated enhancement of EGR1 levels, likely overcoming the concurrent downregulation of
miR-15/107 miRNAs.
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2.3. NEAT1 is Upregulated in AD Temporal Cortex and Hippocampus
We recently showed that miR-15/107 miRNAs level is reduced in the hippocampus and the temporal
cortex, but not in the cerebellum, of AD brains. Furthermore, we showed that increased CDK5R1 mRNA
levels are displayed by AD hippocampus tissue, compared to controls [11]. These data are consistent with
the hypothesis that an increase of CDK5R1 expression, and consequent enhanced CDK5 activity, caused
by downregulation of the miR-15/107 family has a role in the pathogenesis of AD.
To verify whether NEAT1, HOTAIR, and MALAT1 expression is also altered in Alzheimer’s
disease, we quantified their levels by qRT-PCR in the temporal cortex, hippocampus, and cerebellum
of the same AD patients and age-matched healthy controls which were analyzed in our previous work.
Remarkably, we found that NEAT1 was significantly overexpressed in temporal cortex and
hippocampus and downregulated in cerebellum of AD patients, compared to control individuals
(Figure 4A). Comparing NEAT1 distribution among the different brain areas of control individuals
we observed similar expression levels, while NEAT1 was significantly higher in temporal cortex
and hippocampus compared to cerebellum in AD patients (Figure 4B). On the contrary, MALAT1
expression showed no difference between AD patients and controls (Figure 5A), even though higher
levels were detected in cerebellum, compared to temporal cortex and hippocampus, in both groups
(Figure 5B). Finally, HOTAIR was expressed at very low levels in hippocampus and cerebellum and
was not detectable in temporal cortex. Particularly, HOTAIR was downregulated in cerebellum in
AD patients, compared to controls. No difference in HOTAIR expression between hippocampus and
cerebellum was observed in both groups.
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Figure 4. Comparison between the le els of NEAT1 expression in AD and co trol brain tissues.
(A) Dot-Box-plots of the levels o 1 expressio in three different brain ar as (temporal cortex,
hippocam us, and cerebellum) of AD patients (n 10) and controls (n = 8–11). Dark horizontal lines
represent the median, with the box representing the 25th and 75th percentiles, the whiskers the 5th and
95th percentiles. The average of control values was set to 1 and all values were calculated relatively.
NEAT1 levels are significantly upregulated in temporal cortex and hippocampus and downregulated
in cerebellum of AD patients, compared to control individuals. (B) Higher NEAT1 expression levels
were observed in temporal cortex and hippocampus, compared to cerebellum, in AD patients, but not
in control individuals. * p < 0.05, ** p < 0.01, Student’s t-test.
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2.4. NEAT1 and CDK5R1 Overexpression as a Biomarker of AD
In order to verify the existence of a correlation between NEAT1 and CDK5R1 expression in AD
and control brain tissues, we performed a Pearson’s correlation analysis between the normalized
expression levels of NEAT1 and th se previously btained for CDK5R1 [11].
The analysis showed that a significant positive correlation between CDK5R1 and NEAT1 levels
was only displayed by AD patients’ postmortem specimens of hippocampi and temporal cortices with
very significant values of Pearson’s r (Figure 6). In other words, in AD, NEAT1 increases along with
CDK5R1, indicating a peculiar functional relationship (in vitro defined as a negative NEAT1 control
over 5 1) which is specific for AD and that can be eit er a protective response-related mechanism
aimed at limiting (inefficiently) CDK5R1 upregulation or part of t e disease pathogenesis. Notably,
in t e cerebellum, a brain area that is almost unaffected by the disease and in which CDK5R1 does
not appear to be upregulated, the correlation betwee NEAT1 levels and those of CDK5R1 is still
evident only in AD. This observation suggests that in the cerebellum a protective, NEAT1-associated
mechanism might efficiently control CDK5R1 levels.
Another interesting observation is the opposite correlation between the expression of NEAT1 and
miR-15/107 miRNAs in AD brains and controls. Indeed, while in controls we observed high expression
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of miR-15/107 and low expression of NEAT1, in AD patients, to higher NEAT1 levels correspond very
low miR-15/107 levels, particularly in temporal cortex and hippocampus (Figure 7). In conclusion,
a picture emerges in which not only NEAT1 is unable to increase its levels in a sufficient manner to
counteract CDK5R1 increase in AD brains, but also, it loses the ability to positively regulate miR-15/107,
validated negative regulators of CDK5R1. In this way, converging pathological mechanisms based on a
failure of lncRNA NEAT1 and miR-15/107 homeostatic role towards CDK5R1 expression could result
in CDK5R1 upregulation.
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3. Discussion
Cyclin-dependent kinase 5 (CDK5) has a ajor role in CNS develop ent and functioning and
its deregulation can contribute to different pathological events i plicated in the pathogenesis of
Alzhei er’s disease [8]. ono eric CDK5 itself does not display kinase activity and requires, in
order to be active, the association with its regulatory subunits, p35 or p39, although p35, encoded
by the CDK5R1 gene, is considered the most important CDK5 activator [32]. Multiple layers
of regulation govern CDK5R1 expression and ensure p35 levels and CDK5 activity to be tightly
controlled. They include transcriptional activation by EGR1 transcription factor and repression by
LSD1 demethylase [29,30], as well as well various post-transcriptional mechanisms which involve the
binding to the long and evolutionary conserved CDK5R1 3′-UTR of both RNA-binding proteins and
microRNAs [9–11].
In this work, we took into account another class of non-coding RNAs, long non-coding RNAs
(lncRNAs), as potential regulators of CDK5R1 expression. In particular, our attention was focused on
three lncRNAs, NEAT1, HOTAIR, and MALAT1. Our results showed that these three lncRNAs are able
to influence CDK5R1 expression. In particular, NEAT1 and HOTAIR exert a negative regulatory effect
on CDK5R1 levels, while MALAT1 has an opposite, positive action. In addition, all these lncRNAs
were proven to positively regulate the miRNAs belonging to the miR-15/107 family.
We hypothesize that the negative regulatory effect of NEAT1 on CDK5R1 expression might
depend on its capacity to exert a positive control on miR-15/107 levels. Interestingly, we also found
that NEAT1 is significantly overexpressed in temporal cortex and hippocampus of AD patients,
compared to control individuals, suggesting that NEAT1 upregulation can be considered a biomarker
of the disease. Recent studies have linked altered expression and function of long non-coding RNAs to
the pathogenesis of neurodegenerative diseases (reviewed in [22]). In particular, different lncRNAs
have been found to be dysregulated in Alzheimer’s disease (e.g., BACE1-AS and NDM29) and to
be involved in AD pathogenesis by promoting β-amyloid production. In this work we show that,
in vitro, NEAT1 negatively regulates CDK5R1 expression. In line, NEAT1 upregulation in AD patients
would predict a corresponding downregulation of CDK5R1. Notably, this was not the case. Indeed,
in AD brains the expression of both CDK5R1 and NEAT1 is increased compared to healthy controls.
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A possibility is that the negative control of NEAT1 over CDK5R1 levels is not efficient either because
the ratio between CDK5R1 and NEAT1 typical of controls is increased in AD brains (Figure 6), or
because NEAT1 loses its positive control towards miR-15/107 (Figure 7). As a result, we can infer that
the critical NEAT1 level that would be necessary to counteract CDK5R1 expression is not reached in AD
temporal cortex and hippocampus. For these reasons, NEAT1 overexpression as a pathomechanism
in Alzheimer’s disease is unlikely, although our data do not allow to fully reject this hypothesis.
Moreover, several lines of evidence suggest that NEAT1 and paraspeckles may have a neuroprotective
role in neurodegenerative diseases. An increase in paraspeckles formation and NEAT1 levels has
been detected in spinal motor neurons of early phase amyotrophic lateral sclerosis (ALS) patients
compared to control individuals [33] and compromised paraspeckles formation has been proposed
as a pathogenic factor in FUSopathies [34]. Moreover, NEAT1 levels are also increased in the brains
of patients affected by frontotemporal lobar degeneration (FTLD) [35]. Importantly, Sunwoo and
colleagues [36] showed that NEAT1 is overexpressed in Huntington’s disease patients and plays a
protective role against cell injury. These data suggest that NEAT1 may contribute to neuronal survival
in the degenerating brain. Analogously, our work showed that NEAT1 is also overexpressed in AD
patients. In this context, putative beneficial effects of NEAT1 are still unknown. However, enhanced
amounts of CDK5R1 are predicted to cause CDK5 hyperactivation, which is a typical hallmark of the
disease [8]. It is worth noting that CDK5 can phosphorylate p53, which is also known to be upregulated
in AD [37], thereby inducing its stabilization and transcriptional activation, contributing to neuronal
cell death [38]. Remarkably, p53 was recently demonstrated to activate NEAT1 expression [39]. These
findings provide a possible molecular link between CDK5R1 and NEAT1 upregulation in AD brains,
albeit they do not indicate the reason why CDK5R1 escapes NEAT1 control in AD condition.
The negative action exerted by HOTAIR on CDK5R1 expression is likely mediated by different
converging mechanisms. On the one hand, HOTAIR can negatively regulate CDK5R1 at the
post-transcriptional level via the same miR-15/107 miRNA-mediated mechanism as NEAT1, on the
other hand it could regulate CDK5R1 also at the transcriptional level participating to recruiting and
regulating the LSD1 and PRC2 repressing complexes [28]. Interestingly, HOTAIR also represses the
transcription of BDNF [27], which normally induces the ERK-mediated expression of CDK5R1 [29].
On the contrary, our silencing experiments suggest that MALAT1 positively affect CDK5R1
expression. Since reduction of miR-15/107 levels after MALAT1 silencing would predict an increase in
the amount of CDK5R1 mRNA, as expected for their inhibitory action, there must be other predominant
regulatory mechanisms leading to CDK5R1 upregulation by MALAT1. As we have also shown that
MALAT1 silencing causes a strong reduction in the levels of EGR1, which is the main activator of
CDK5R1 transcription, we thus speculate that MALAT1 can enhance CDK5R1 expression mainly by
upregulating EGR1 transcription factor through activation of ERK/MAPK signaling pathway [31].
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Moreover, the activation of this pathway is known to play a critical role in promoting neurite
outgrowth [31]. Given that the p35/CDK5 complex is also essential for neurite outgrowth during
neuronal differentiation [40], our evidence raises the interesting hypothesis that MALAT1 induces
axonal elongation via CDK5R1/p35 upregulation.
Mounting evidence suggests that lncRNAs can function as miRNA sponges, by sequestering
the mature miRNA molecules and preventing the binding to their target mRNAs [41]. However, this
mechanism is predicted to increase—or leave unchanged—the levels of the sequestered miRNAs
when the lncRNA acting as sponge is silenced [14,42]. Since we observed that the silencing of NEAT1,
HOTAIR, and MALAT1 lead to a reduction of miR-15/107 miRNAs, we hypothesize that this effect
could be mediated by a positive regulatory action of these lncRNAs on transcription factors that
promote the expression of this family of miRNAs or, alternatively, by their interaction with the
microprocessor to enhance pri-miRNA processing, as already demonstrated for NEAT1 [43].
Overall, our data suggest that lncRNAs can provide a further layer and a higher degree of
complexity to the control of CDK5R1 expression. In addition, we show that NEAT1 is upregulated in
AD brain, possibly as a part of a protective mechanism against neuronal death, and can be considered
a marker of the disease and represents a potential pharmacological target for therapeutic intervention
in AD.
4. Materials and Methods
4.1. Cell Cultures
HeLa cells (code CCL-2, ATCC, Manassas, VA, USA) were cultured in DMEM high glucose
(Euroclone, Pero, Italy) medium with 10% fetal bovine serum (FBS) (Euroclone), 100 U/mL
penicillin-streptomycin (Euroclone) and 0.01 mM L-glutamine (Euroclone). Cultures were maintained
at 37 ◦C in a 5% CO2 incubator.
4.2. Brain Tissues
Post-mortem frozen brain tissue samples of AD patients and age- and sex-matched non-demented
individuals were obtained from MRC London Neurodegenerative Diseases Brain Bank (King’s College
London), Newcastle Brain Tissue Resource (Newcastle University), and South West Dementia Brain
Bank (University of Bristol) and are described in [10]. The approval of the Ethics Committee of the
University of Milan was obtained for the use of post-mortem tissues for research purposes (Project
identification code: RV_RIC_AT16MVENT_M, 15 June 2016).
4.3. Antisense Oligonucleotides Transfection
2′-O-methyl phosphorothioate antisense oligonucleotides (2′OMe-PS ASO) were designed as
described by [44] (NEAT1 1473, HOTAIR 1259, MALAT1 5326, NC1) and purchased from Consorzio
Futuro in Ricerca, Università degli Studi di Ferrara (Ferrara, Italy).
ASOs were used at 10 nM concentration. 200 × 103 HeLa cells were seeded in 6-well plates in
order to extract total RNA. The cells were transfected 24 h after seeding with 2′OMe-PS ASOs, using
Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) transfection reagent according to
the manufacturer’s instructions. Cell extracts were prepared for analysis 24 h after the transfection.
4.4. Real-Time PCR
Total RNA from transfected/nontransfected cells and from brain tissues (100 mg of each sample
tissue) was isolated using TRIzol reagent (Thermo Fisher Scientific), according to the manufacturer’s
instructions. Concentration and purity of RNA were measured using the Nanodrop spectrophotometer
(ThermoFisher Scientific). All RNA samples had an A260/280 value of 1.8–2.1.
For the measurement of CDK5R1, EGR1 mRNA, NEAT1, HOTAIR, and MALAT1 RNA,
a DNase reaction was performed on 1 µg of total RNA using RQ1 RNase-Free Dnase (Promega,
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Madison, WI, USA) and then cDNA was synthetized in 20 µL reactions using the High Capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scientific), according to the manufacturer’s
instructions. SYBR Green Real-Time PCR was performed using the GoTaq qPCR Master
Mix (Promega) and the following primers: CDK5R1 fw: TGAGCGGGTCTAGTGGAAAG;
CDK5R1 rev: AGCAGCAGACAAGGGGGTAG; EGR1 fw: GAGCACCTGACCGCAGAGTC;
EGR1 rev: GTGTTGCCACTGTTGGGTGC; HOTAIR fw: GGCAAGACGGGCACTCACAG;
HOTAIR rev: CTGGGCGTTCATGTGGCGAG; MALAT1 fw: AGGGAAAGCGAGTGGTTGGT;
MALAT1 rev: GAAATCGGCCTACGTCCCCA; NEAT1 fw: CGGAGGTGAGGGGTGGTCTG;
NEAT1 rev: GCAGTCCCCGCCTGTCAAAC; EIF4A2 fw: GGTCAGGGTCAAGTCGTGTT;
EIF4A2 rev: CCCCCTCTGCCAATTCTGTG; CYC1 fw: TAGAGTTTGACGATGGCACCC;
CYC1 rev: CGTTTTCGATGGTCGTGCTC; SYP fw: CTTCGCCATCTTCGCCTTTG; SYP
rev: TACACTTGGTGCAGCCTGAAG; ENO2 fw: CTGAAGCCATCCAAGCGTGC; ENO2 rev:
CCCACCACCAGGTCAGCAAT. 20 µL PCR reactions were prepared with 2× SYBR Green mix
containing 1.6 µL of reverse transcriptase product and 0.4 µL of each primer (10 µM). The PCR mixtures
were incubated at 95 ◦C for 3 min, followed by 40 cycles of 95 ◦C for 10 s, 60 ◦C for 20 s, and 72 ◦C
for 10 s. The calculation of gene expression levels was based on the ∆∆Ct method in transfection
experiments and on the ∆Ct method for gene expression analysis in brain tissues. The geometric
mean of the expression values of EIF4A2 and CYC1 housekeeping genes was used as internal control
in transfection experiments, while gene expression levels in brain tissues were normalized on the
geometric mean of the same housekeeping genes and the neuronal markers SYP and ENO2.
For the measurement of miRNAs, a two-step Taq-Man real-time PCR assay was performed
using primers and probes obtained from Thermo Fisher Scientific. The reverse transcriptase reaction
was performed using the TaqMan MicroRNA Reverse Transcription kit (Thermo Fisher Scientific),
according to the manufacturer’s instructions. cDNA was synthesized from 50 ng of total RNA in 15 µL
reactions, using the stem-loop primer for miR-15a (ID000389), miR-15b (ID000390), miR-16 (ID000391),
miR-103 (ID000439), miR-107 (ID000443), miR-195 (ID000494), and U6 snRNA (ID001973). The PCR
reaction (20 µL) contained 1.3 µL of reverse transcriptase product, 10 µL of Taq-Man Universal PCR
Master Mix (Thermo Fisher Scientific) and 1 µL of the appropriate TaqMan MicroRNA Assay (20×)
containing primers and probes for the miR of interest. The PCR mixtures were incubated at 95 ◦C for
10 min, followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 60 s. The expression of miRs was based on
the ∆∆Ct methods, using U6 snRNA as an endogenous control. All PCRs were performed in triplicate
using an iQ5 Real-Time PCR detection system (Bio-Rad, Hercules, CA, USA).
4.5. Statistical Analysis
Each experiment was carried out at least three times. Histograms represent the mean values and
bars indicate the standard deviation of the mean. The box plots show median, 25th and 75th percentile
values and whiskers to the minimum and maximum value. The statistical significance of the results
was determined using Student’s t-test, with data considered significant when p < 0.05. The degree of
linear relationship between CDK5R1 gene and NEAT1 expression levels was calculated using Pearson’s
correlation coefficient (r value). The p value was calculated from an extra sum-of-squares F test.
Author Contributions: Conceptualization, M.S., F.R., E.B., and M.V.; Formal analysis, M.S., B.G., F.R., E.B., and
M.V.; Funding acquisition, E.B., F.R., and M.V.; Investigation, M.S. and B.G.; Methodology, M.S., B.G., and M.V.;
Project administration, M.V.; Resources, E.B. and M.V.; Supervision, M.V.; Validation, M.V.; Visualization, M.S.
and M.V.; Writing—original draft, M.S. and M.V.; Writing—review & editing, M.S., B.G., F.R., E.B., and M.V.
Acknowledgments: The authors would like to thank the MRC London Neurodegenerative Diseases Brain Bank,
the Newcastle Brain Tissue Resource, and the South West Dementia Brain Bank (SWDBB) for providing brain
tissue for this study. The SWDBB is supported by BRACE (Bristol Research into Alzheimer’s and Care of the
Elderly), Brains for Dementia Research and the Medical Research Council. This work was supported by the
Academic Grant “Bando BIOMETRA—Fondi Incentivo alla Ricerca 2015” (Università degli studi di Milano, project
no. RV_RIC_AT16MVENT_M) to M.V., the Ministero dell’Istruzione, dell’Università e della Ricerca (award no.
Epigenomics Flagship Project), Telethon Foundation project (award no. GGP14074) and Fondazione Cariplo
(award no. 2016-0204) to E.B., and Fondazione Cariplo (award no. 2014-0972) to F.R.
Int. J. Mol. Sci. 2018, 19, 2022 12 of 14
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Hebert, L.E.; Weuve, J.; Scherr, P.A.; Evans, D.A. Alzheimer disease in the United States (2010–2050) estimated
using the 2010 census. Neurology 2013, 80, 1778–1783. [CrossRef] [PubMed]
2. Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease.
Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [CrossRef] [PubMed]
3. Desler, C.; Lillenes, M.S.; Tønjum, T.; Rasmussen, L.J. The role of mitochondrial dysfunction in the progression
of Alzheimer’s disease. Curr. Med. Chem. 2017, 24. [CrossRef] [PubMed]
4. Jiang, T.; Chang, R.C.; Rosenmann, H.; Yu, J.T. Advances in Alzheimer’s disease: From bench to bedside.
Biomed. Res. Int. 2015, 2015, 202676. [CrossRef] [PubMed]
5. Wang, J.Z.; Grundke-Iqbal, I.; Iqbal, K. Kinases and phosphatases and tau sites involved in Alzheimer
neurofibrillary degeneration. Eur. J. Neurosci. 2007, 25, 59–68. [CrossRef] [PubMed]
6. Fischer, A.; Sananbenesi, F.; Schrick, C.; Spiess, J.; Radulovic, J. Cyclin-dependent kinase 5 is required for
associative learning. J. Neurosci. 2002, 22, 3700–3707. [CrossRef] [PubMed]
7. McLinden, K.A.; Trunova, S.; Giniger, E. At the fulcrum in health and disease: Cdk5 and the balancing acts
of neuronal structure and physiology. Brain Disord. Ther. 2012, 2012 (Suppl. 1), 001. [CrossRef] [PubMed]
8. Liu, S.L.; Wang, C.; Jiang, T.; Tan, L.; Xing, A.; Yu, J.T. The Role of Cdk5 in Alzheimer’s Disease. Mol. Neurobiol.
2016, 53, 4328–4342. [CrossRef] [PubMed]
9. Moncini, S.; Bevilacqua, A.; Venturin, M.; Fallini, C.; Ratti, A.; Nicolin, A.; Riva, P. The 3′ untranslated region
of human Cyclin-Dependent Kinase 5 Regulatory subunit 1 contains regulatory elements affecting transcript
stability. BMC Mol. Biol. 2007, 8, 111. [CrossRef] [PubMed]
10. Zuccotti, P.; Colombrita, C.; Moncini, S.; Barbieri, A.; Lunghi, M.; Gelfi, C.; de Palma, S.; Nicolin, A.; Ratti, A.;
Venturin, M.; et al. hnRNPA2/B1 and nELAV proteins bind to a specific U-rich element in CDK5R1 3′-UTR
and oppositely regulate its expression. Biochim. Biophys. Acta 2014, 1839, 506–516. [CrossRef] [PubMed]
11. Moncini, S.; Lunghi, M.; Valmadre, A.; Grasso, M.; del Vescovo, V.; Riva, P.; Denti, M.A.; Venturin, M. The
miR-15/107 Family of microRNA Genes Regulates CDK5R1/p35 with Implications for Alzheimer’s Disease
Pathogenesis. Mol. Neurobiol. 2017, 54, 4329–4342. [CrossRef] [PubMed]
12. Khorkova, O.; Hsiao, J.; Wahlestedt, C. Basic biology and therapeutic implications of lncRNA.
Adv. Drug Deliv. Rev. 2015, 87, 15–24. [CrossRef] [PubMed]
13. Nie, L.; Wu, H.J.; Hsu, J.M.; Chang, S.S.; Labaff, A.M.; Li, C.W.; Wang, Y.; Hsu, J.L.; Hung, M.C.
Long non-coding RNAs: Versatile master regulators of gene expression and crucial players in cancer.
Am. J. Transl. Res. 2012, 4, 127–150. [PubMed]
14. Bayoumi, A.S.; Sayed, A.; Broskova, Z.; Teoh, J.P.; Wilson, J.; Su, H.; Tang, Y.L.; Kim, I.M. Crosstalk between
Long Noncoding RNAs and MicroRNAs in Health and Disease. Int. J. Mol. Sci. 2016, 17, 356. [CrossRef]
[PubMed]
15. Li, Y.; Wang, X. Role of long noncoding RNAs in malignant disease (Review). Mol. Med. Rep. 2016, 13,
1463–1469. [CrossRef] [PubMed]
16. Faghihi, M.A.; Modarresi, F.; Khalil, A.M.; Wood, D.E.; Sahagan, B.G.; Morgan, T.E.; Finch, C.E.;
St Laurent, G., 3rd; Kenny, P.J.; Wahlestedt, C. Expression of a noncoding RNA is elevated in Alzheimer’s
disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med. 2008, 14, 723–730. [CrossRef]
[PubMed]
17. Faghihi, M.A.; Zhang, M.; Huang, J.; Modarresi, F.; Van der Brug, M.P.; Nalls, M.A.; Cookson, M.R.;
St-Laurent, G., 3rd; Wahlestedt, C. Evidence for natural antisense transcript-mediated inhibition of microRNA
function. Genome Biol. 2010, 11, R56. [CrossRef] [PubMed]
18. Chakravarty, D.; Sboner, A.; Nair, S.S.; Giannopoulou, E.; Li, R.; Hennig, S.; Mosquera, J.M.; Pauwels, J.;
Park, K.; Kossai, M.; et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of
prostate cancer. Nat. Commun. 2014, 5, 5383. [CrossRef] [PubMed]
19. West, J.A.; Davis, C.P.; Sunwoo, H.; Simon, M.D.; Sadreyev, R.I.; Wang, P.I.; Tolstorukov, M.Y.; Kingston, R.E.
The long noncoding RNAs NEAT1 and MALAT1 bind active chromatin sites. Mol. Cell 2014, 55, 791–802.
[CrossRef] [PubMed]
20. Fox, A.H.; Lamond, A.I. Paraspeckles. Cold Spring Harb. Perspect. Biol. 2010, 2, a000687. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2022 13 of 14
21. Hirose, T.; Virnicchi, G.; Tanigawa, A.; Naganuma, T.; Li, R.; Kimura, H.; Yokoi, T.; Nakagawa, S.; Bénard, M.;
Fox, A.H.; et al. NEAT1 long noncoding RNA regulates transcription via protein sequestration within
subnuclear bodies. Mol. Biol. Cell 2014, 25, 169–183. [CrossRef] [PubMed]
22. Riva, P.; Ratti, A.; Venturin, M. The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel
Mechanisms of Pathogenesis. Curr. Alzheimer Res. 2016, 13, 1219–1231. [CrossRef] [PubMed]
23. Tripathi, V.; Ellis, J.D.; Shen, Z.; Song, D.Y.; Pan, Q.; Watt, A.T.; Freier, S.M.; Bennett, C.F.; Sharma, A.;
Bubulya, P.A.; et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by
modulating SR splicing factor phosphorylation. Mol. Cell 2010, 39, 925–938. [CrossRef] [PubMed]
24. Gutschner, T.; Hämmerle, M.; Diederichs, S. MALAT1—A paradigm for long noncoding RNA function in
cancer. J. Mol. Med. (Berl.) 2013, 91, 791–801. [CrossRef] [PubMed]
25. Wang, P.; Wu, T.; Zhou, H.; Jin, Q.; He, G.; Yu, H.; Xuan, L.; Wang, X.; Tian, L.; Sun, Y.; et al. Long
noncoding RNA NEAT1 promotes laryngeal squamous cell cancer through regulating miR-107/CDK6
pathway. J. Exp. Clin. Cancer Res. 2016, 35, 22. [CrossRef] [PubMed]
26. Zhang, H.; Wang, G.; Yin, R.; Qiu, M.; Xu, L. Comprehensive Identification of MicroRNAs Regulated by
Long Non-coding RNA MALAT1. Zhongguo Fei Ai Za Zhi 2016, 19, 247–251. [CrossRef] [PubMed]
27. Yu, X.; Li, Z. Long non-coding RNA HOTAIR: A novel oncogene (Review). Mol. Med. Rep. 2015, 12,
5611–5618. [CrossRef] [PubMed]
28. Tsai, M.C.; Manor, O.; Wan, Y.; Mosammaparast, N.; Wang, J.K.; Lan, F.; Shi, Y.; Segal, E.; Chang, H.Y.
Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329, 689–693.
[CrossRef] [PubMed]
29. Toffolo, E.; Rusconi, F.; Paganini, L.; Tortorici, M.; Pilotto, S.; Heise, C.; Verpelli, C.; Tedeschi, G.; Maffioli, E.;
Sala, C.; et al. Phosphorylation of neuronal Lysine-Specific Demethylase 1 LSD1/KDM1A impairs
transcriptional repression by regulating interaction with CoREST and histone deacetylases HDAC1/2.
J. Neurochem. 2014, 128, 603–616. [CrossRef] [PubMed]
30. Harada, T.; Morooka, T.; Ogawa, S.; Nishida, E. ERK induces p35, a neuron-specific activator of Cdk5,
through induction of Egr1. Nat. Cell Biol. 2001, 3, 453–459. [CrossRef] [PubMed]
31. Chen, L.; Feng, P.; Zhu, X.; He, S.; Duan, J.; Zhou, D. Long non-coding RNA Malat1 promotes neurite
outgrowth through activation of ERK/MAPK signalling pathway in N2a cells. J. Cell. Mol. Med. 2016, 20,
2102–2110. [CrossRef] [PubMed]
32. Ko, J.; Humbert, S.; Bronson, R.T.; Takahashi, S.; Kulkarni, A.B.; Li, E.; Tsai, L.H. p35 and p39 are essential for
cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 2001, 21, 6758–6771. [CrossRef]
[PubMed]
33. Nishimoto, Y.; Nakagawa, S.; Hirose, T.; Okano, H.J.; Takao, M.; Shibata, S.; Suyama, S.; Kuwako, K.;
Imai, T.; Murayama, S.; et al. The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces
paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral sclerosis. Mol. Brain
2013, 6, 31. [CrossRef] [PubMed]
34. Shelkovnikova, T.A.; Robinson, H.K.; Troakes, C.; Ninkina, N.; Buchman, V.L. Compromised paraspeckle
formation as a pathogenic factor in FUSopathies. Hum. Mol. Genet. 2014, 23, 2298–2312. [CrossRef] [PubMed]
35. Tollervey, J.R.; Curk, T.; Rogelj, B.; Briese, M.; Cereda, M.; Kayikci, M.; König, J.; Hortobágyi, T.;
Nishimura, A.L.; Zupunski, V.; et al. Characterizing the RNA targets and position-dependent splicing
regulation by TDP-43. Nat. Neurosci. 2011, 14, 452–458. [CrossRef] [PubMed]
36. Sunwoo, J.S.; Lee, S.T.; Im, W.; Lee, M.; Byun, J.I.; Jung, K.H.; Park, K.I.; Jung, K.Y.; Lee, S.K.; Chu, K.; et al.
Altered Expression of the Long Noncoding RNA NEAT1 in Huntington's Disease. Mol. Neurobiol. 2017, 54,
1577–1586. [CrossRef] [PubMed]
37. Hooper, C.; Meimaridou, E.; Tavassoli, M.; Melino, G.; Lovestone, S.; Killick, R. p53 is upregulated in
Alzheimer’s disease and induces tau phosphorylation in HEK293a cells. Neurosci. Lett. 2007, 418, 34–37.
[CrossRef] [PubMed]
38. Lee, J.H.; Kim, H.S.; Lee, S.J.; Kim, K.T. Stabilization and activation of p53 induced by Cdk5 contributes to
neuronal cell death. J. Cell Sci. 2007, 120, 2259–2271. [CrossRef] [PubMed]
39. Mello, S.S.; Sinow, C.; Raj, N.; Mazur, P.K.; Bieging-Rolett, K.; Broz, D.K.; Imam, J.F.C.; Vogel, H.; Wood, L.D.;
Sage, J.; et al. Neat1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev. 2017,
31, 1095–1108. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2022 14 of 14
40. Nikolic, M.; Dudek, H.; Kwon, Y.T.; Ramos, Y.F.; Tsai, L.H. The cdk5/p35 kinase is essential for neurite
outgrowth during neuronal differentiation. Genes Dev. 1996, 10, 816–825. [CrossRef] [PubMed]
41. Rinn, J.L.; Chang, H.Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 2012, 81, 145–166.
[CrossRef] [PubMed]
42. Yoon, J.H.; Abdelmohsen, K.; Gorospe, M. Functional interactions among microRNAs and long noncoding
RNAs. Semin. Cell Dev. Biol. 2014, 34, 9–14. [CrossRef] [PubMed]
43. Jiang, L.; Shao, C.; Wu, Q.J.; Chen, G.; Zhou, J.; Yang, B.; Li, H.; Gou, L.T.; Zhang, Y.; Wang, Y.; et al.
NEAT1 scaffolds RNA-binding proteins and the Microprocessor to globally enhance pri-miRNA processing.
Nat. Struct. Mol. Biol. 2017, 24, 816–824. [CrossRef] [PubMed]
44. Lennox, K.A.; Behlke, M.A. Cellular localization of long non-coding RNAs affects silencing by RNAi more
than by antisense oligonucleotides. Nucleic Acids Res. 2016, 44, 863–877. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
